Use of pneumococcal polysaccharide vaccine in children: what is the evidence

Current Opinion in Infectious Diseases, 05/04/2012

Whether the immune response to PPV23, non–PCV13 serotypes is sufficient to confer clinical benefit to at–risk children depends on their age, underlying disease and the immunogenicity of individual serotypes. Given the theoretical risk of memory B–cell depletion following PPV23 vaccination, it is not clear how best to maintain protection in those at–risk children who remain susceptible to IPD.

Print Article Summary Cat 2 CME Report